More: HIV Management 2008: The New York Course

NY Course 2008: Pharmacology of Antiretrovirals CME

April 24 - 25, 2008, New York, NY

Author Information and Disclosures

This activity was developed in collaboration with HIV Management 2008: The New York Course.

HIV Management 2008: The New York Course is an online educational collaboration between Albert Einstein College of Medicine and Medscape

Release Date: May 30, 2008; Valid for credit through May 30, 2009

Credits Available
Physicians - maximum of 1.5 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

  1. ART With Hepatic DysfunctionCharles Flexner, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
  2. ART With Renal DysfunctionCourtney V. Fletcher, PharmDAvailable As: Slides/Audio | Slides/Transcript | Audio
  3. HIV PharmacogenomicsDavid J. Back, PhDAvailable As: Slides/Audio | Slides/Transcript | Audio
Downloadable Slides
ART With Hepatic Dysfunction
Downloadable PowerPoint Slides by Charles Flexner, MD
ART With Renal Dysfunction
Downloadable PowerPoint Slides by Courtney V. Fletcher, PharmD
HIV Pharmacogenomics
Downloadable PowerPoint Slides by David J. Back, PhD

Legal Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and were developed in collaboration with the HIV Management 2008: The New York Course.

Copyright © 2008 Medscape.
Merck, BMS
Learning Objectives
Upon completion of this activity, participants will be able to:
  1. To understand the impact of hepatic dysfunction on the pharmacokinetics of antiretroviral drugs
  2. To understand the potential impact of aging on hepatic function and the pharmacokinetics of antiretroviral drugs
  3. To describe current recommendations for dose modifications of approved antiretroviral drugs in patients with advanced liver disease
  4. To describe mechanisms of antiretroviral-drug-induced renal dysfunction
  5. To delineate the effects of renal dysfunction on the pharmacokinetic characteristics of antiretroviral drugs
  6. To recommend dose-adjustment strategies for antiretroviral drugs in settings of renal dysfunction
  7. To discuss pharmacologic principles underpinning the potential use of pharmacogenetic tests in optimization of antiretroviral therapy
  8. To demonstrate how the identification of the MHC haplotype B*5701 as a strong genetic predisposing factor for abacavir hypersensitivity reaction can be regarded as a prime example of translational research
  9. To examine the status of other potential genotypic-phenotypic correlations for drug-associated adverse events (efavirenz, atazanavir, tenofovir)
Authors and Disclosures

Charles W. Flexner, MD
Disclosure: Charles W. Flexner, MD, has disclosed that he has served as a consultant or advisor to AGI Therapeutics Research, Bristol-Myers Squibb, Genzyme, Inhibitex, Merck, Tibotec, and Vertex. Dr. Flexner has also disclosed that he has received honoraria for lectures and educational course participation from Abbott and Gilead, and that he has received research grant support from Boehringer Ingelheim, GlaxoSmithKline, and Tibotec.


Courtney V. Fletcher, PharmD
Disclosure: Courtney V. Fletcher, PharmD, has disclosed that he has served as a consultant to Abbott, Bristol-Myers Squibb, GlaxoSmithKline, and Roche.


David J. Back, PhD
Disclosure: David J. Back, PhD, has disclosed that he has received grants and/or research support from Pfizer, GlaxoSmithKline, Boehringer Ingelheim, Tibotec, and Bristol-Myers Squibb. Dr. Back has also disclosed that he has served as a consultant to Boehringer Ingelheim, Tibotec, and Bristol-Myers Squibb, and that he has served on the speaker's bureau for GlaxoSmithKline, Boehringer Ingelheim, and Tibotec. Dr. Back has also disclosed that he is a major stockholder of Delphic Diagnostics.


 
Albert Einstein College of Medicine
Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

All other healthcare professionals completing continuing education credit for this activity will be issued a certificate of participation.

Albert Einstein College of Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.